These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33964453)

  • 41. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
    Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
    Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
    [No Abstract]   [Full Text] [Related]  

  • 42. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
    Kuo HK; Sun IT; Chung MY; Chen YH
    Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Screening for retinopathy of prematurity-the most important changes in the new German guidelines 2020].
    Li JQ; Kellner U; Lorenz B; Stahl A; Krohne TU
    Ophthalmologe; 2021 Dec; 118(12):1240-1244. PubMed ID: 33931789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
    Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
    Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants.
    Kong L; Demny AB; Sajjad A; Bhatt AR; Devaraj S
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1649-54. PubMed ID: 27054517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Commentary: Are we there yet? Role of anti-vascular endothelial growth factor and laser in the management of retinopathy of prematurity.
    Sindal MD; Yadav D
    Indian J Ophthalmol; 2021 Aug; 69(8):2176-2177. PubMed ID: 34304204
    [No Abstract]   [Full Text] [Related]  

  • 48. Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 Retinopathy of Prematurity.
    Hamichi SE; Saigal K; Anzaldo EF; Gold A; Berrocal AM; Murray TG
    Ophthalmic Surg Lasers Imaging Retina; 2022 Mar; 53(3):159-163. PubMed ID: 35272561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.
    Morrison D; Shaffer J; Ying GS; Binenbaum G;
    J AAPOS; 2018 Apr; 22(2):128-133. PubMed ID: 29548840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment for retinopathy of prematurity in Sweden 2008-2021: Reduced gestational age of treated infants and remaining differences in treatment type and recurrence rates between hospitals.
    Holmström G; Hellström A; Teär Fahnehjelm K; Gränse L; Sandgren Hochhard K; Sunnqvist B; Tornqvist K; Tsamadou D; Wallin A; Larsson E
    Acta Ophthalmol; 2024 Jun; 102(4):401-408. PubMed ID: 37698061
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
    Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
    Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
    ; Hartnett ME; Wallace DK; Dean TW; Li Z; Boente CS; Dosunmu EO; Freedman SF; Golden RP; Kong L; Prakalapakorn SG; Repka MX; Smith LE; Wang H; Kraker RT; Cotter SA; Holmes JM
    JAMA Ophthalmol; 2022 Apr; 140(4):337-344. PubMed ID: 35446359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
    Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
    Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atypical case of retinopathy of prematurity with candle wax-like preretinal deposits and its surprising response to intravitreal antivascular endothelial growth factor.
    Shah MS; Padhy SK; Sahu S; Padhi TR
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity: An International Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2022 Dec; 129(12):1380-1388. PubMed ID: 35863512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
    Tan QQ; Christiansen SP; Wang J
    PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anatomical and refractive outcomes in patients with treated retinopathy of prematurity.
    Lolas M; Tuma A; Zanolli M; Agurto R; Stevenson R; Ossandón D
    Arch Soc Esp Oftalmol; 2017 Oct; 92(10):472-476. PubMed ID: 28624314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab.
    Mohr FH; Fischer HS; Czernik C; Müller B; Bührer C
    Eur J Ophthalmol; 2024 Jan; 34(1):95-101. PubMed ID: 37218176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Topical glycerine for corneal clouding during retinal laser photocoagulation for retinopathy of prematurity.
    Lambat S; Gupta S; Nagar R; Nangia P; Dogra M; Nangia V
    Eur J Ophthalmol; 2023 Jul; 33(4):1755-1757. PubMed ID: 36703255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.